News & Videos - REGENERON PHARMACEUTICALS INC. - Page 5

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair PR Newswire TARRYTOWN, N.Y. and WASHINGTON, May 13, 2022 $75,000 Top Award Goes to 17-year-old Robert Sansone for pioneering invention to improve electric motor efficiency in the largest international STEM competition for teens TARRYTOWN, N.Y. and WASHINGTON , May 13, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society)...

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair PR Newswire TARRYTOWN, N.Y. and WASHINGTON, May 13, 2022 $75,000 Top Award Goes to 17-year-old Robert Sansone for pioneering invention to improve electric motor efficiency in the largest international STEM competition for teens TARRYTOWN, N.Y. and WASHINGTON , May 13, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science...

Regeneron Reports First Quarter 2022 Financial and Operating Results PR Newswire TARRYTOWN, N.Y., May 4, 2022 TARRYTOWN, N.Y. , May 4, 2022 /PRNewswire/ -- First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 25% First quarter 2022 EYLEA ® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021 First quarter 2022 Dupixent ® global net sales (c) (recorded by Sanofi) increased 43% to $1.81 billion...

Regeneron Announces Investor Conference Presentations PR Newswire TARRYTOWN, N.Y., May 2, 2022 TARRYTOWN, N.Y. , May 2, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: BofA Securities Healthcare Conference at 1:20 p.m. PT ( 4:20 p.m. ET ) on Tuesday, May 10, 2022 Goldman Sachs 43 rd Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m . ET) on Tuesday, June 14, 2022 The sessions may be accessed from the "Investors &...

Shareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Regeneron PR Newswire MILWAUKEE, April 19, 2022 MILWAUKEE , April 19, 2022 /PRNewswire/ -- Ademi LLP is investigating Checkmate (NASDAQ:CMPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Regeneron. Click here to learn how to join the action: https://www.ademilaw.com/case/checkmate-pharmaceuticals-inc or call Guri Ademi...

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types PR Newswire TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022 Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy...

Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022...

U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19 PR Newswire TARRYTOWN, N.Y., April 14, 2022 Regeneron continues to progress its next generation antibodies, and has initiated a first-in-human trial TARRYTOWN, N.Y. , April 14, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the...

Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation PR Newswire TARRYTOWN, N.Y. and PARIS, April 7, 2022 Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children Data reinforce well-established safety profile of Dupixent TARRYTOWN, N.Y. and PARIS , April 7, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals,...

Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 PR Newswire TARRYTOWN, N.Y, April 5, 2022 TARRYTOWN, N.Y , April 5, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM...

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis PR Newswire TARRYTOWN, N.Y. and PARIS, April 4, 2022 If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis There are approximately 160,000 patients in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments TARRYTOWN, N.Y. and PARIS ,...

Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis PR Newswire TARRYTOWN, N.Y. and PARIS, March 26, 2022 TARRYTOWN, N.Y. and PARIS , March 26, 2022 /PRNewswire/ -- Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions There are currently no approved systemic treatments for prurigo nodularis;...

Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation PR Newswire TARRYTOWN, N.Y. and WASHINGTON, March 15, 2022 $250,000 top award goes to Christine Ye in the nation's oldest and most prestigious science and math competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, March 15, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and...

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein PR Newswire CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 28, 2022 CAMBRIDGE, Mass. and TARRYTOWN, N.Y. , Feb. 28, 2022 /PRNewswire/ -- Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent...

Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis PR Newswire TARRYTOWN, N.Y. and PARIS, Feb. 26, 2022 TARRYTOWN, N.Y. and PARIS , Feb. 26, 2022 /PRNewswire/ -- Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease...

Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria PR Newswire TARRYTOWN, N.Y. and PARIS, Feb. 26, 2022 TARRYTOWN, N.Y. and PARIS , Feb. 26, 2022 /PRNewswire/ -- In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients...

Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program PR Newswire TARRYTOWN, N.Y. and PARIS, Feb. 18, 2022 TARRYTOWN, N.Y. and PARIS , Feb. 18, 2022 /PRNewswire/ -- In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futility Positive results from a previous Phase 3 trial in...

Regeneron Announces Investor Conference Presentations PR Newswire TARRYTOWN, N.Y., Feb. 17, 2022 TARRYTOWN, N.Y. , Feb. 17, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: Cowen 42 nd Annual Health Care Conference at 1:30 p.m. ET on Tuesday , March 8, 2022 Oppenheimer 32 nd Annual Healthcare Conference at 10:00 a.m. ET on Tuesday , March 15, 2022 Barclays Global Healthcare Conference at 8:00 a.m. ET on Wednesday, March 16,...

Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting PR Newswire TARRYTOWN, N.Y., Feb. 11, 2022 TARRYTOWN, N.Y. , Feb. 11, 2022 /PRNewswire/ -- Trial met primary safety endpoint and no new safety signals seen through week 44 Results favored aflibercept 8 mg in visual acuity, drying and other anatomical measures through week 44 Phase 3 results in wet age-related macular degeneration and diabetic macular edema...

FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis PR Newswire TARRYTOWN, N.Y. and PARIS, Feb. 10, 2022 TARRYTOWN, N.Y. and PARIS , Feb. 10, 2022 /PRNewswire/ -- If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S....